MD Anderson and Summit Therapeutics announced a strategic five-year collaboration to accelerate the development of ivonescimab, a novel PD-1/VEGF bispecific antibody.
Tag: bispecific antibody
Immunotherapy Drug Development Pipeline Continues Significant Growth in 2020 Despite Global Pandemic Impact
Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them.